Life
JAM | Feb 21, 2024

Surveys point to lasting benefits of psilocybin therapy for depression, anxiety

/ Our Today

administrator
Reading Time: 2 minutes

Jamaica-based psilocybin-assisted company MycoMeditation Inc. says two years of surveys are pointing to a magic mushroom therapy retreats providing tangible benefits to people with major depressive disorder, generalised anxiety disorder, and social anxiety disorder.

The Treasure Beach company, releasing its findings, found that people with these conditions experienced significant and lasting improvements in their mental health after attending the retreats.

Utilising specific questionnaires to measure how severe the symptoms of each condition were before and after the retreats, the company noticed positive results that lasted for a whole year.

The surveys further demonstrated that the benefits from MycoMeditations’ retreats were as good as, or even better than, the outcomes from clinical studies, including those by COMPASS Pathways, which is researching a synthetic version of psilocybin.

“Importantly, these improvements in mental health conditions like depression and anxiety lasted for a full year after the retreat. The findings suggest that taking psilocybin in several doses over a short period might be eSective, and that personalised dosing could be more beneficial than the same dose for everyone based on their body weight,” the company added.

Aerial view of MycoMeditations operations in Treasure Beach, St Elizabeth. (Photo: Trip Advisor)

MycoMeditations has been operating since 2014 in Jamaica and uses a modern approach to psychotherapy with psilocybin.

The company’s recent report not only supports the idea that psilocybin can help with mental health issues outside of strict clinical research but also emphasises the success of their retreat model. This model includes group therapy and private psilocybin sessions in nature.

“MycoMeditations would like to thank our guests, our team, and our academic partner for their support and collaboration in the assembly of these data sets,” said CEO and head facilitator Justin Townsend. “As the global acceptance of psilocybin therapy broadens, we’re pleased to have hard evidence that very favorably compares the results of our retreats to leading clinical research in the field.”

Comments

What To Read Next